InvestorsHub Logo
Followers 25
Posts 1336
Boards Moderated 0
Alias Born 11/15/2016

Re: None

Tuesday, 07/04/2017 5:12:31 PM

Tuesday, July 04, 2017 5:12:31 PM

Post# of 203912
This is part of why R&d costs are so small, Sheba has a small right, or Royalties I will say. For doing certain studies. This means Sheba is a believer in there study. Otherwise they would be taking a substantial hit in the long run if the products don't work. It's right in there filings. I recommend to all not to respond to patent talks any longer as it's been hammered on now for 3 months. If an investor wants to buy in he should not be taking the advice from self appointed patent experts and go by the companies filings that are LEGALLY bound to the SEC.

This is strait out of there filings about R&d



While we retain full ownership on our intellectual property rights that we conceived prior to the signing of the research collaboration and license agreements with Sheba Academic Medical Center, the psoriasis and fibromyalgia agreements with Sheba provide that all intellectual property rights that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis.
Pursuant to the collaboration agreements, we are expected to pay Sheba $170,000 for conducting the multiple myeloma trial between the 3rd quarter of 2015 and the second quarter of 2016. In addition, we commenced pre-clinical studies on the treatment of psoriasis during the second quarter of 2016. Pursuant to the collaboration agreements, we are obliged to pay Sheba $85,000 throughout 2017 for conducting the safety study for the cream. We currently have the financial resources to fund our current obligations under these agreements,